Kairos Pharma, LTD.KAPA
Price (close)
$1.77
Market cap
$6.0M
P/E
—
Revenue (TTM)
—
Net income
-$5.8M
Dividend yield
—
1-year total return
-77.8%
Net margin
—
Revenue growth
—
Debt / equity
—
What Kairos Pharma, LTD. does.
are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in
immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer,
lung cancer, breast cancer, and glioblastoma. We are driven by innovative science to develop novel and transformative drug therapies
Revenue and profit, by fiscal year.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net income | — | -$1.8M | -$2.6M | -$5.4M |
More on KAPA.
- Kairos Pharma, LTD. summary
- Kairos Pharma, LTD. financial statements
- Kairos Pharma, LTD. key metrics
- Kairos Pharma, LTD. health scores and style box
- Kairos Pharma, LTD. earnings
- Kairos Pharma, LTD. dividends
- Kairos Pharma, LTD. valuation
- Kairos Pharma, LTD. ownership and insiders
- Kairos Pharma, LTD. peers
Figures from Kairos Pharma, LTD.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.